Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in Telix's stock price [2][7]. - The SEC is investigating Telix for potentially misleading disclosures about the development of its prostate cancer therapeutic candidates [7]. Allegations of Misrepresentation - The complaint claims that Telix and its executives overstated the progress of their therapeutic candidates and misrepresented the reliability of their third-party supply chain and manufacturing partners [2][3]. - It alleges a dual regulatory failure, with the SEC questioning development disclosures and the FDA rejecting a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures led to substantial losses for investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is urging affected investors to contact them to discuss their rights and potential recovery [4][5].